Tectonic Therapeutic, Inc. (TECX)
(Delayed Data from NSDQ)
$22.09 USD
+0.21 (0.96%)
Updated Aug 13, 2025 04:00 PM ET
After-Market: $22.11 +0.02 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Fundamental Charts
About Return on Equity (TTM)
Tectonic Therapeutic, Inc.'s return on equity, or ROE, is -30.13% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.40%. While this shows that TECX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
TECX 22.09 +0.21(0.96%)
Will TECX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TECX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TECX
Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High?
TECX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TECX
Analysts’ Top Healthcare Picks: Stereotaxis (STXS), Tectonic Therapeutic (TECX)
Tectonic Therapeutic GAAP EPS of -$1.07
12 Health Care Stocks Moving In Thursday's After-Market Session
Tectonic Therapeutic (TECX) Receives New Buy Rating from Truist Securities | TECX Stock News
Truist Recommends Buy for Tectonic Therapeutic (TECX) with $64 Target | TECX Stock News